Latest news with #Natera
Business Insider
2 days ago
- Business
- Business Insider
Natera price target raised to $195 from $185 at Morgan Stanley
Morgan Stanley analyst Patrick Wood raised the firm's price target on Natera (NTRA) to $195 from $185 and keeps an Overweight rating on the shares post the Q2 report. The firm says the company reported a solid beat with momentum across the business. It sees upside potential to estimates in the back half of 2025. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
2 days ago
- Business
- Business Insider
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (CTKB), Natera (NTRA) and Warby Parker (WRBY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytek Biosciences (CTKB – Research Report), Natera (NTRA – Research Report) and Warby Parker (WRBY – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cytek Biosciences (CTKB) Morgan Stanley analyst Yuko Oku maintained a Hold rating on Cytek Biosciences on August 8 and set a price target of $4.00. The company's shares closed last Friday at $4.03, close to its 52-week low of $3.97. Currently, the analyst consensus on Cytek Biosciences is a Moderate Buy with an average price target of $4.80, a 17.1% upside from current levels. In a report issued on August 6, TD Cowen also maintained a Hold rating on the stock with a $4.00 price target. Natera (NTRA) Morgan Stanley analyst Patrick Wood reiterated a Buy rating on Natera on August 8 and set a price target of $195.00. The company's shares closed last Friday at $151.95. According to Wood is a 1-star analyst with an average return of -2.2% and a 52.2% success rate. Wood covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Organogenesis Holdings, and Zimmer Biomet Holdings. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Natera with a $202.46 average price target, representing a 25.0% upside. In a report issued on July 28, Evercore ISI also initiated coverage with a Buy rating on the stock with a $170.00 price target. Warby Parker (WRBY) Morgan Stanley analyst Alexandra Straton maintained a Hold rating on Warby Parker on August 8 and set a price target of $20.00. The company's shares closed last Friday at $23.33. According to Straton is a 4-star analyst with an average return of 5.2% and a 53.2% success rate. Straton covers the NA sector, focusing on stocks such as Lululemon Athletica, Bath & Body Works, and Abercrombie Fitch. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Warby Parker with a $25.86 average price target, representing a 6.8% upside. In a report issued on August 5, Roth MKM also maintained a Hold rating on the stock with a $24.00 price target.
Yahoo
6 days ago
- Health
- Yahoo
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
Launch supported by strong assay performance in first milestone readout of the landmark EXPAND clinical trial AUSTIN, Texas, August 07, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test (NIPT) for inherited conditions. When a pregnant patient is identified as a carrier of a recessive single-gene condition, medical guidelines recommend partner testing in order to determine the risk for the baby to be affected by the condition1; however, in some cases the biological father is unavailable for testing. The Fetal Focus test was designed to address this unmet need. Now if a pregnant patient tests positive with Natera's Horizon™ carrier screen for one of the five most commonly tested genes, and if the father is unavailable for testing, Fetal Focus can screen the fetus directly for that gene by simply analyzing a sample of the mother's blood. Fetal Focus is validated for the analysis of five genes: CFTR (cystic fibrosis), SMN1 (spinal muscular atrophy), HBA1 and HBA2 (alpha-thalassemia), and HBB (beta-hemoglobinopathies, including sickle cell disease). The launch is supported by data from EXPAND, a large, prospective, blinded clinical trial. The study, which was initiated in 2023, has enrolled approximately 1,300 participants to date, reflecting a diverse, multi-ethnic population from leading academic medical centers and maternal fetal medicine clinics. EXPAND is designed to be the defining clinical trial in the category, with all outcomes, including both positive and negative results, confirmed by genetic truth using prenatal or postnatal diagnostic testing. In its first milestone readout (n=101) from EXPAND, the Fetal Focus test demonstrated 91% sensitivity and successfully identified 5/5 fetuses affected by homozygous variants.2,3 Homozygous cases, where the fetus inherits the same condition-causing variant from both parents, are especially challenging to detect. Fetal Focus uses Natera's proprietary LinkedSNP™ technology to improve detection of these cases across diverse populations. "Having access to a noninvasive option like Fetal Focus can provide critical information to support decision-making during pregnancy, especially in situations where partner testing isn't possible," said John Williams, M.D., chief principal investigator for EXPAND and director of reproductive genetics at Cedars-Sinai. "Fetal Focus adds another important offering within our comprehensive reproductive health portfolio – furthering our commitment to launching products that address clinical gaps in care and are supported by rigorous clinical validation," said Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women's health at Natera. "The EXPAND study has been underway for several years, and we're pleased to release this first milestone readout." References ACOG Committee Opinion #690, Mar 2017. Internal data on file. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results. EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). Accessed July 2025. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio
Yahoo
02-08-2025
- Health
- Yahoo
Natera initiates trial of Signatera test for breast cancer
Natera has announced the initiation of the Phase II TEODOR trial of its Signatera test aimed at replacing chemotherapy with endocrine therapy before surgery in certain breast cancer patients. The multicentre, randomised controlled trial (RCT) focuses on women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer who are responsive to endocrine treatment and test negative with Signatera. Academic research organisation Austrian Breast & Colorectal Cancer Study Group sponsored the trial, which plans to enrol 250 subjects across 15 Austrian sites. This trial seeks to assess the endocrine therapy's efficacy in comparison to chemotherapy in those who are Signatera-negative, to minimise the use of pre-operative chemotherapy and its associated side effects. After receiving an endocrine therapy course for four weeks, subjects who remain Signatera-negative and exhibit a favourable response as per the Ki-67 proliferation index measurement are set to be randomised to continue with endocrine therapy or chemotherapy. The primary goal of the TEODOR trial is the response rate to neoadjuvant therapy, gauged by pathological complete response (pCR) and modified Preoperative Endocrine Prognostic Index (PEPI) score, across endocrine and chemotherapy trial arms. Secondary goals encompass long-term effects such as recurrence of breast cancer and overall survival rates. Signatera is a custom-built blood test for identifying molecular residual disease (MRD) in the form of circulating tumour DNA. Natera oncology medical director Angel Rodriguez said: 'With the TEODOR trial, our goal is to identify patients who may be able to safely forgo chemotherapy. 'We are proud to collaborate with ABCSG on this important trial, and we hope this study will support the role of Signatera in guiding neoadjuvant therapy in breast cancer.' The test is covered by Medicare for those with stage IIb and higher breast cancer. In May 2025, Natera announced outcomes from a study assessing the Signatera MRD test in those with soft tissue and bone sarcomas. "Natera initiates trial of Signatera test for breast cancer" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
01-08-2025
- Business
- Yahoo
Evercore ISI Initiates Coverage on Natera (NTRA) with Outperform Rating
Natera, Inc. (NASDAQ:NTRA) is one of the high growth stocks outside tech analysts are bullish on. Evercore ISI Group has initiated coverage on Natera Inc. (NASDAQ: NTRA) with an 'Outperform' rating and a $170 price target, signaling optimism about the company's strategic positioning in the growing genetic testing space. With Natera trading at $135.81 as of Monday's close, the target implies a potential upside of roughly 25.2%. This initiation reflects Evercore's confidence in Natera's ability to capture meaningful market share through its differentiated platform, particularly in high-growth areas like minimal residual disease (MRD) testing in oncology and non-invasive prenatal testing (NIPT). The firm's pricing also suggests it sees earnings momentum or adoption trends that may not yet be fully reflected in the current valuation. Unlike a broad sector endorsement, this coverage initiation appears to be a conviction call based on company-specific catalysts. These could include upcoming clinical data, reimbursement tailwinds, or commercial traction in new markets. While risks remain, such as competition and regulatory shifts, the bullish stance hints that Evercore believes the risk-reward profile is favorable. If Natera delivers on key execution fronts over the coming quarters, the target may prove conservative, particularly if revenue re-acceleration or gross margin expansion materializes. Natera develops and markets genetic testing solutions for oncology, women's health, and organ health applications. While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
